This is an aggregated industry headline. Read the full story at BioPharma Dive →
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival succeeded against migraines and two deals were struck.
By BioPharma Dive
· Jul 10, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Bayer has addressed its need for a capital infusion under a deal to secure 3 billion euros ($3.4 billion) in e…
The WeekFierceBiotech ↗
KKR, the global investment giant, has launched Allyntra as a new, precision-engineered solutions platform for …
The WeekBriefing
The FDA has expanded the use of the Padcev-Keytruda combination in bladder cancer, intensifying competition fo…